

## DCP3 Series Acknowledgments

*Disease Control Priorities*, third edition (*DCP3*) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions, we convey our acknowledgment and appreciation. First and foremost, we would like to thank our 33 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 160 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network. Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, and (currently) Damian Walker for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for *DCP3* while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington's Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the *DCP3* Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics & Policy; Centre for Chronic Disease Control; Centre for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee assures quality and intellectual rigor of the highest order for *DCP3*.

The National Academy of Medicine, in collaboration with the InterAcademy Medical Panel, coordinated the peer-review process for all *DCP3* chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, and Rachel Pittluck managed this effort and provided critical and substantive input.

The World Bank External and Corporate Relations Publishing and Knowledge division provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, the publisher; Mary Fisk, Nancy Lammers, Rumit Pancholi, and Deborah Naylor for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that supported the preparation and dissemination of *DCP3*.

We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of noncommunicable diseases (July 2013)
- Institute of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics & Policy (Quality and Uptake meeting, September 2013;

reproductive and maternal health volume consultation, November 2013)

- National Cancer Institute, cancer consultation (November 2013)
- Union for International Cancer Control, cancer consultation (November 2013, December 2014)

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added invaluable guidance in applying and improving the extended cost-effectiveness analysis method. Shane Murphy, Zachary Olson, Elizabeth Brouwer, Kristen Danforth, and David Watkins provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes. The efforts of these individuals were absolutely critical to producing this series, and we are thankful for their commitment.

## Series and Volume Editors

### VOLUME EDITORS

#### **Vikram Patel**

Vikram Patel is Professor of International Mental Health and Wellcome Trust Principal Research Fellow at the London School of Hygiene & Tropical Medicine (LSHTM). He is a psychiatrist whose work focuses on the epidemiology and treatment of mental disorders in low-resource settings. He was the Founding Director of the Centre for Global Mental Health at the LSHTM and is the Co-Director of the Centre for Control of Chronic Conditions at the Public Health Foundation of India. In 2011, Dr. Patel served on the Government of India's Mental Health Policy group, which produced India's first national mental health policy in 2014.

#### **Dan Chisholm**

Dan Chisholm is a Health Systems Adviser in the Department of Mental Health and Substance Abuse at the World Health Organization. His main areas of work include development and monitoring of global mental health plans and activities, technical assistance to Member States on mental health system strengthening, and analysis of the costs and cost-effectiveness of strategies for reducing the global burden of mental disorders and other noncommunicable diseases.

#### **Tarun Dua**

Tarun Dua is a Medical Officer working in the Evidence, Research and Action on Mental and Brain Disorders unit in the Department of Mental Health and Substance Abuse at the World Health Organization. Dr. Dua serves as the focal point for neurological disorders in the organization.

#### **Ramanan Laxminarayan**

Ramanan Laxminarayan is Vice President for Research and Policy at the Public Health Foundation of India, and he directs the Center for Disease Dynamics, Economics & Policy in Washington, DC, and New Delhi. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was one of the key architects of the Affordable Medicines Facility—malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

#### **María Elena Medina-Mora**

María Elena Medina-Mora is the General Director for the National Institute of Psychiatry Ramón de la Fuente Muñiz in Mexico. She is a member of the National System of Researchers. Dr. Medina-Mora is a full researcher of the National Institutes of Health and has a teaching appointment in the National Autonomous University of Mexico and as Adjunct Professor in the Harvard T. H. Chan School of Public Health. She is also member of the World Health Organization's Expert Committee on Addictions.

### SERIES EDITORS

#### **Dean T. Jamison**

Dean T. Jamison is a Senior Fellow in Global Health Sciences at the University of California, San Francisco, and an Emeritus Professor of Global Health at the University of Washington. He previously held academic

appointments at Harvard University and the University of California, Los Angeles; he was an economist on the staff of the World Bank, where he was lead author of the World Bank's *World Development Report 1993: Investing in Health*. He was lead editor of *DGP2*. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the National Academy of Sciences. He recently served as Co-Chair and Study Director of *The Lancet's* Commission on Investing in Health.

### **Rachel Nugent**

Rachel Nugent is a Research Associate Professor in the Department of Global Health at the University of Washington. She was formerly Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991–97, she was Associate Professor and Department Chair in Economics at Pacific Lutheran University. She has advised the World Health Organization, the U.S. government, and nonprofit organizations on the economics and policy environment of noncommunicable diseases.

### **Hellen Gelband**

Hellen Gelband is Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, then Resources for the Future, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the National Academies, and a number of international organizations.

### **Susan Horton**

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies,

and the International Development Research Centre, among others, in work carried out in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as Associate Provost of Graduate Studies at the University of Waterloo, Vice-President Academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto Scarborough.

### **Prabhat Jha**

Prabhat Jha is the Founding Director of the Centre for Global Health Research at St. Michael's Hospital and holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is Lead Investigator of the Million Death Study in India, which quantifies the causes of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

### **Ramanan Laxminarayan**

See the list of Volume Editors.

### **Charles N. Mock**

Charles N. Mock, MD, PhD, FACS, has training as both a trauma surgeon and an epidemiologist. He worked as a surgeon in Ghana for four years, including at a rural hospital (Berekum) and at the Kwame Nkrumah University of Science and Technology (Kumasi). In 2005–07, he served as Director of the University of Washington's Harborview Injury Prevention and Research Center. In 2007–10, he worked at the World Health Organization (WHO) headquarters in Geneva, where he was responsible for developing the WHO's trauma care activities. In 2010, he returned to his position as Professor of Surgery (with joint appointments as Professor of Epidemiology and Professor of Global Health) at the University of Washington. His main interests include the spectrum of injury control, especially as it pertains to low- and middle-income countries: surveillance, injury prevention, prehospital care, and hospital-based trauma care. He is President (2013–15) of the International Association for Trauma Surgery and Intensive Care.

## Contributors

### **Emiliano Albanese**

Department of Psychiatry, University of Geneva, Geneva, Switzerland

### **Margaret Barry**

National University of Ireland Galway, Galway, Ireland

### **Amanda J. Baxter**

School of Public Health, University of Queensland, Brisbane, Queensland, Australia; Queensland Centre for Mental Health Research, Wacol, Queensland, Australia

### **Vladimir Carli**

Swedish National Center for Suicide Research and Prevention, Karolinska Institutet, Stockholm, Sweden

### **Fiona J. Charlson**

School of Public Health, University of Queensland, Herston, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

### **Pamela Y. Collins**

U.S. National Institute of Mental Health, Bethesda, Maryland, United States

### **Abigail Colson**

Center for Disease Dynamics, Economics & Policy, Washington, DC, United States; Department of Management Science, University of Strathclyde, Glasgow, Scotland

### **Louisa Degenhardt**

National Drug and Alcohol Research Centre, University of New South Wales Australia, Sydney, New South Wales, Australia; Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia; Institute for Health

Metrics and Evaluation, University of Washington, Seattle, Washington, United States

### **Catherine O. Egbe**

University of KwaZulu-Natal, Durban, South Africa; Center for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, United States

### **Holly E. Erskine**

School of Public Health, University of Queensland, Herston, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

### **Sara Evans-Lacko**

Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

### **Valery Feigin**

National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand

### **Abebaw Fekadu**

Addis Ababa University, Addis Ababa, Ethiopia

### **Alize J. Ferrari**

School of Public Health, University of Queensland, Herston, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

### **Pantelimon Giannakopoulos**

Department of Psychiatry, University of Geneva, Geneva, Switzerland

**Petra Gronholm**

Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

**David Gunnell**

University of Bristol, Bristol, United Kingdom

**Wayne D. Hall**

Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, Queensland, Australia

**Steven Hyman**

Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States

**David Jernigan**

Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States

**Nathalie Jette**

University of Calgary, Calgary, Alberta, Canada

**Kjell Arne Johansson**

University of Bergen, Bergen, Norway

**Carol Levin**

Department of Global Health, University of Washington, Seattle, Washington, United States

**Mattias Linde**

Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; Norwegian Advisory Unit on Headaches, St. Olavs Hospital, Trondheim, Norway

**Crick Lund**

Department of Psychiatry and Mental Health, Alan J. Flisher Centre for Public Mental Health, University of Cape Town, Cape Town, South Africa; Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

**John Marsden**

National Addiction Centre, King's College London, London, United Kingdom

**Itamar Megiddo**

Center for Disease Dynamics, Economics & Policy, Washington, DC, United States; Department of Management Science, University of Strathclyde, Glasgow, Scotland

**Cathrine Mihalopoulos**

Deakin University, Melbourne, Victoria, Australia

**Maristela Monteiro**

Pan American Health Organization, Washington DC, United States

**Aditi Nigam**

Center for Disease Dynamics, Economics & Policy, Washington, DC, United States

**Rachana Parikh**

Public Health Foundation of India, New Delhi, India

**Inge Petersen**

University of KwaZulu-Natal, Durban, South Africa

**Michael R. Phillips**

Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Departments of Psychiatry and Global Health, Emory University, Atlanta, Georgia, United States

**Martin J. Prince**

Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

**Atif Rahman**

University of Liverpool, Liverpool, United Kingdom

**Neha Raykar**

Public Health Foundation of India, New Delhi, India

**Tania Real**

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico

**Jürgen Rehm**

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

**Jacqueline Roberts**

Autism Centre of Excellence, Griffith University, Brisbane, Queensland, Australia

**Robin Room**

Centre for Alcohol Policy Research, La Trobe University, Melbourne, Victoria, Australia; Centre for Social Research on Alcohol and Drugs, Stockholm University, Stockholm, Sweden

**Diego Sánchez-Moreno**

Ministry of Health, Mexico City, Mexico

**James G. Scott**

University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia; Metro North Mental Health, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

**Maya Semrau**

Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

**Rahul Shidhaye**

Public Health Foundation of India, New Delhi, India; CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands

**Morton M. Silverman**

Suicide Prevention Resource Center, Education Development Center, Waltham, Massachusetts, United States, The University of Colorado Denver School of Medicine, Aurora, Colorado, United States; The Jed Foundation, New York, New York, United States

**Timothy J. Steiner**

Norwegian University of Science and Technology, Trondheim, Norway; Imperial College London, London, United Kingdom

**Emily Stockings**

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

**Kirsten Bjerkreim Strand**

University of Bergen, Bergen, Norway

**John Strang**

National Addiction Centre, King's College London, London, United Kingdom

**Kiran T. Thakur**

Columbia University College of Physicians and Surgeons, New York, New York, United States

**Graham Thornicroft**

Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom

**Stéphane Verguet**

Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

**Lakshmi Vijayakumar**

SNEHA, Voluntary Health Services, Chennai, India; Centre for Youth Mental Health, University of Melbourne, Melbourne, Victoria, Australia

**Theo Vos**

Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

**Harvey A. Whiteford**

School of Public Health, University of Queensland, Herston, Queensland, Australia; Queensland Centre for Mental Health Research, Wacol, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States





## Advisory Committee to the Editors

**Anne Mills, Chair**

Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

**Olusoji Adeyi**

Director, Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

**Kesetebirhan Admasu**

Minister of Health, Addis Ababa, Ethiopia

**George Alleyne**

Director Emeritus, Pan American Health Organization, Washington, DC, United States

**Ala Alwan**

Director, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

**Rifat Atun**

Professor, Global Health Systems, Harvard University, Boston, Massachusetts, United States

**Zulfiqar Bhutta**

Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

**Agnes Binagwaho**

Minister of Health, Kigali, Rwanda

**Mark Blecher**

Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

**Patricia Garcia**

Dean, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru

**Roger Glass**

Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

**Amanda Glassman**

Director, Global Health Policy, Center for Global Development, Washington, DC, United States

**Glenda Gray**

Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

**Demissie Habte**

Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

**Richard Horton**

Editor, *The Lancet*, London, United Kingdom

**Edward Kirumira**

Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

**Peter Lachmann**

Professor, University of Cambridge, Cambridge, United Kingdom

**Lai Meng Looi**

Professor, University of Malaya, Kuala Lumpur, Malaysia

**Adel Mahmoud**

Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

**Anthony Measham**

World Bank, Washington, DC, United States (retired)

**Carol Medlin**

Senior Health and Nutrition Specialist,  
Health, Nutrition, and Population Global Practice,  
World Bank, Washington, DC, United States

**Alvaro Moncayo**

Researcher, Universidad de los Andes, Bogotá,  
Colombia

**Jaime Montoya**

Executive Director, Philippine Council for Health  
Research and Development, Taguig City, the  
Philippines

**Ole Norheim**

Professor, University of Bergen, Bergen, Norway

**Folashade Omokhodion**

Professor, University College Hospital, Ibadan,  
Nigeria

**Toby Ord**

President, Giving What We Can, Oxford,  
United Kingdom

**K. Srinath Reddy**

President, Public Health Foundation of India,  
New Delhi, India

**Sevkat Ruacan**

Dean, Koç University School of Medicine, Istanbul,  
Turkey

**Jaime Sepúlveda**

Executive Director, Global Health Sciences, University  
of California, San Francisco, San Francisco, California,  
United States

**Richard Skolnik**

Lecturer, Health Policy Department, Yale School of  
Public Health, New Haven, Connecticut, United States

**Stephen Tollman**

Professor, University of the Witwatersrand,  
Johannesburg, South Africa

**Jürgen Unutzer**

Professor, Department of Psychiatry, University of  
Washington, Seattle, Washington, United States

**Damian Walker**

Senior Program Officer, Bill & Melinda Gates  
Foundation, Seattle, Washington, United States

**Ngaire Woods**

Director, Global Economic Governance Programme,  
Oxford University, Oxford, United Kingdom

**Nopadol Wora-Urai**

Professor, Department of Surgery, Phramongkutklao  
Hospital, Bangkok, Thailand

**Kun Zhao**

Researcher, China National Health Development  
Research Center, Beijing, China

## Reviewers

**Sergio Aguilar-Gaxiola**

University of California, Davis, School of Medicine,  
Sacramento, California, United States

**Pierre K. Alexandre**

Management Department, College of Business,  
Florida Atlantic University, Boca Raton, Florida,  
United States

**Peter Anderson**

Newcastle University, Institute for Health and Society,  
Newcastle, United Kingdom

**Margaret Barry**

National University of Ireland Galway, School of Health  
Sciences, Galway, Ireland

**Angelina Brotherhood**

Centre for Public Health, Liverpool John Moores  
University, Liverpool, United Kingdom

**Anja Busse**

United Nations Office on Drugs and Crime, Vienna,  
Austria

**Dixon Chibanda**

Department of Community Medicine, University of  
Zimbabwe, Harare, Zimbabwe

**Mary De Silva**

Centre for Global Mental Health, London School  
of Hygiene & Tropical Medicine, London,  
United Kingdom

**Tedla W. Giorgis**

Office of the Minister, Ministry of Health, Addis Ababa,  
Ethiopia

**Alexander Grinshpoon**

Israel Institute of Technology, Haifa, Israel

**Yasemin Gürsoy-Özdemir**

Department of Neurology, Koç University School of  
Medicine, Istanbul, Turkey

**Murad M. Khan**

Aga Khan University, Karachi, Pakistan

**Rena Kurs**

Sha'ar Menashe Mental Health Center, Sha'ar Menashe,  
Israel

**David Leon**

London School of Hygiene & Tropical Medicine,  
London, United Kingdom

**Ron Manderscheid**

National Association of County Behavioral Health and  
Developmental Disability Directors, Washington, DC,  
United States

**Pallab K. Maulik**

George Institute for Global Health, India, New Delhi,  
India

**David McDaid**

London School of Economics and Political Science,  
London, United Kingdom

**Nicole M. Monteiro**

Center for Healing and Development, Washington, DC,  
United States

**Chiadi U. Onyike**

The Johns Hopkins Hospital, Baltimore, Maryland,  
United States

**Gregory Simon**

Group Health Research Institute, Seattle, Washington,  
United States

**Jürgen Unützer**

Department of Psychiatry and Behavioral Sciences,  
University of Washington, Seattle, Washington,  
United States

**Steven D. Vannoy**

University of Massachusetts, Boston, Boston,  
Massachusetts, United States

**Chiu-Wan Ng**

Faculty of Medicine, University Malaya, Kuala Lumpur,  
Malaysia

## Index

*Boxes, figures, notes, and tables are indicated by b, f, n, and t respectively.*

### A

- ACE (Assessing Cost-Effectiveness) prevention framework, 188
- acupuncture, 91, 101
- addiction. *See* illicit drug dependence
- ADHD. *See* attention-deficit hyperactivity disorder
- adolescents
  - ADHD and, 146
  - alcoholic consumption, heavy episodic drinking by, 128
  - CBT for depression in, 222
  - health loss in, 36
  - interventions for
    - drug use, early intervention for at-risk youth, 114
    - mental health policies and plans, 148
  - onset, 8, 194
  - Resourceful Adolescent Programme-Adolescent version (RAP-A) program, 229–30, 230*t*
  - suicides of, 171
- adult mental disorders, 67–86
  - burden of disease, 67–68
  - extended-stay facilities to treat, 203
  - interventions for, 73–78
    - case detection and diagnosis, 77
    - collaborative and stepped care, 77
    - community outreach, 77–78, 79
    - community platform interventions, 73–74
    - cost-effectiveness of, 78
    - early intervention services, 77
    - family, 74, 79
    - health care platform interventions, 74–78
    - information and communication packages, 78
    - mental health awareness campaigns, 73
    - mental health legislation, 73
    - occupational therapy, 76, 79
    - packages of care, 76–77
    - pharmacologic and psychological treatment, 74–76, 75–76*t*, 79
    - population platform interventions, 73
    - schools, 73–74
    - workplace, 73
  - mood and anxiety disorders, 68–72
    - anxiety disorders, 70–71. *See also* anxiety disorders
    - bipolar disorder, 71–72. *See also* bipolar disorder
    - depressive disorder, 69–70. *See also* depression
  - psychotic disorders, 72–73
  - recommendations for, 78–79
  - risk factors, 68
  - schizophrenia, 72–73. *See also* schizophrenia
  - suicide and, 169
  - training gatekeepers to identify people with, 223
  - YLDs and, 67–68, 68*f*
- advertising bans on alcoholic beverages, 139
- AEDs (anti-epileptic drugs), 88, 90, 91, 240
- affordability. *See* cost-effectiveness and affordability of interventions
- Africa. *See also specific countries and regions*
  - alcohol consumption in, 129
  - epilepsy in, 90
  - illicit drug trade in, 111
  - migraines in, 100
  - suicide prevention organizations in, 176
  - suicide rates in, 164, 169, 170
- age as factor. *See also* adolescents; elderly persons
  - for anxiety disorders, 70–71
  - for cause-specific deaths from MNS disorders, 53, 54*t*

- childhood disorders resulting in adult disorders, 146, 194
- for dementia, 8
- of suicide and self-harm, 164, 165*t*, 166–67*f*, 166*f*
- Alcoholics Anonymous, 137
- alcohol use disorders, 127–43
  - age of death attributable to, 53, 54*t*
  - binge drinking, 49, 128
  - burden of disease, 32–34*t*, 128–30
  - challenges for LMICs, 138–39
  - classification of beverages, 127
  - consequences, 129
  - co-occurring disorders and, 49–50
  - cost-effectiveness of interventions for, 19, 20*f*, 137–38, 139–40, 221–22, 226, 227*t*
  - DALYs and, 129
  - deaths associated with, 7*t*, 44, 129
  - fetal alcohol syndrome disorders (FASD), 128, 135, 139
  - GBD findings of excess mortality for
    - estimated number of cause-specific and excess deaths, 46*t*, 49
    - gender differences, 45, 46*f*
  - gender differences, 128–29
  - globalization of alcohol beverages industry, 128
  - indigenous communities and
    - community platform interventions, 135, 136*t*
    - prohibition, 131, 131*t*
  - industry role, 127–28
  - interventions for, 130–37
    - advertising bans, 139
    - availability control and licensing of sellers, 138
    - blood alcohol concentration (BAC) testing of drivers, 134
    - breath testing of drivers, 134
    - community platform interventions, 130–31, 135, 136*t*
    - control of unrecorded market, 133, 138–39
    - cross-border shopping, 133
    - delivery platforms, 14*t*
    - demand reduction strategies, 229, 229*f*
    - driving countermeasures, 134–35, 139
    - education campaigns, 139
    - family-based interventions, 135, 139
    - health care platform interventions, 135–37
    - individual-based, 130
    - law enforcement measures to reduce driving while impaired, 132*t*
    - mass media campaigns, 135
    - medical and social detoxification, follow-up, and referral, 136, 137*t*, 139
    - population platform interventions, 130, 131–35, 131*t*
    - pregnant women and, 135, 139
    - pricing and market regulation, 138
    - primary health care, 13–14*t*, 15
    - prohibition and partial bans, 131, 132*t*
    - quasi-experimental studies, 130
    - reducing availability of alcohol, 131
    - school-based, 19, 139
    - screening and brief interventions, 135–36, 136*t*, 139, 140
    - self-help and support groups, 136–37
    - sobriety checkpoints, 134
    - specialist health care delivery, 15
    - suspension of driver's license, 135
    - taxation, 131*t*, 132–33, 138, 221, 229
    - warning labels, 135, 139
  - liver cirrhosis and, 50
  - patterns of, 128
  - prohibition and partial bans, 131, 132*t*
  - public health considerations, 128
  - quasi-experimental studies, 130
  - recommendations for LMICs, 139
  - societal response, 130
  - suicide and, 50, 129, 169, 175
  - unintentional injuries and violence, 50, 129
  - YLLs and, 43–45, 45*f*, 53, 55, 55*t*
  - Alzheimer's disease. *See also* dementia
    - burden of disease, 32–34*t*, 94
    - DALYs and, 95
    - deaths associated with, 7*t*, 37, 53, 54*t*
    - goal to identify cure by 2025, 99
    - pharmacological interventions, 96, 98
  - amphetamine dependence. *See also* illicit drug dependence
    - amphetamine-type stimulants, 109
    - burden of disease, 32–34*t*
    - consumption trends, 111
    - deaths associated with, 7*t*, 110
      - age of death, 54*t*
    - estimated number of cause-specific and excess deaths for, 46*t*, 50*f*
    - prevalence in Southeast Asia and Australasia, 37
    - rates of dependence, 110
    - YLLs and, 43
  - Anderson, P., 19
  - anorexia nervosa, 3. *See also* eating disorders
  - antidepressants. *See* depression
  - anti-epileptic drugs (AEDs), 88, 90, 91, 240
  - antipsychotics
    - for dementia patients, 53, 96–97
    - for schizophrenia, 48
  - anxiety disorders, 70–71
    - age of onset, 70–71
    - burden of disease, 32–34*t*, 36, 70–71
    - childhood, 145
    - clinical features and course, 70

- DALYs associated with, 36
  - deaths associated with, 7*t*
  - epidemiological surveys on, 38
  - epidemiology, 70–71
  - estimated number of cause-specific and excess deaths for, 46*t*, 49
  - gender differences, 68
  - generalized anxiety disorder, 70
  - interventions for, 9*t*. *See also* adult mental disorders
    - limited access to, 12
    - pharmacologic and psychological treatment, 74–76, 75*t*
    - primary health care, 13–14*t*, 15
    - self-care, 15
  - obsessive-compulsive disorder (OCD), 70
  - panic disorder, 70
  - simple phobias, 70
  - social anxiety disorder, 70
  - YLDs and, 68, 68*f*
  - Asia. *See also specific countries and regions*
    - amphetamine dependence in, 37
    - drug users, detention and treatment of, 58
    - illicit substance use in, 111
  - Asperger's syndrome, 36. *See also* autistic spectrum disorders
  - aspirin, 100–101
  - Assessing Cost-Effectiveness (ACE) prevention framework, 188
  - Atkins diet, 91
  - Atlas on Substance Use* (WHO), 137
  - attention-deficit hyperactivity disorder (ADHD)
    - age of occurrence, 146
    - bipolar disorder and, 49
    - burden of disease, 32–34*t*, 36
    - cost-effectiveness of pharmacological interventions, 155
    - defined, 145
    - estimated number of cause-specific and excess deaths for, 46*t*, 49
    - interventions for, 9*t*, 12
      - medications, 154
      - school-based, 192
  - Australia
    - collaborative stepped care approach in, 210
    - drug dependence in
      - court-mandated treatment, 113
      - economic costs, 111
      - interventions, cost of, 118, 119
    - indigenous communities and alcohol consumption in, 131
    - mental health first aid course in, 188
    - methadone maintenance and buprenorphine maintenance in, 226
    - parenting interventions in, 155, 223
    - planning and consultation with primary health care staff in, 210
    - Positive Parenting Program (Triple P), 223
  - autistic spectrum disorders
    - age of cause-specific and excess deaths attributed to, 47*f*
    - burden of disease, 32–34*t*, 36
    - co-occurring disorders with, 48–49
    - deaths associated with, 7*t*
    - estimated number of cause-specific and excess deaths for, 46*t*, 47*f*, 48–49
    - interventions for, 9*t*
- B**
- Babor, T. F., 135
  - Baker-Henningham, H., 150
  - Balanced Care Model, 207
  - Beijing Suicide Research and Prevention Center, 176
  - best practice interventions, 4*b*, 12, 15, 22, 56, 183, 184*t*, 188
  - binge drinking, 49, 128
  - bipolar disorder, 2
    - ADHD and, 49
    - adult bipolar disorder, 71–72
    - age of cause-specific and excess deaths attributed to, 47*f*
    - burden of disease, 32*t*, 34*t*, 71–72
    - clinical features and course, 71
    - cost-effectiveness of interventions for, 19, 227*t*
      - community-based vs. hospital-based services, 228
    - deaths associated with, 7*t*
    - epidemiology, 71–72
    - estimated number of cause-specific and excess deaths for, 46*t*, 47*f*, 48
    - gender differences, 68
    - interventions for. *See also* adult mental disorders
      - pharmacologic and psychological treatment, 74–76, 75*t*
      - specialist health care delivery, 15
    - YLDs and, 68, 68*f*
  - birth trauma, 185
  - blood alcohol concentration (BAC) testing of drivers, 134
  - Boussinesq, M., 52
  - Brazil
    - childhood mental and developmental disorders in
      - CBT for children with anxiety disorders, 154
      - community-based interventions, 149
    - collaborative stepped care approach in, 210
    - cost-effectiveness of drug therapy for schizophrenia and depression in, 225
    - primary care interventions in, 208
      - training of primary care workers, 210
    - specialists training primary health care staff in, 210

- suicide in, 169, 170, 171, 172
    - Program for Promotion of Life and Suicide Prevention, 176
    - teacher training program to identify and assess mental health problems in, 191*b*
  - breath testing of drivers, 134
  - brief psychological intervention
    - for alcohol use disorders, 135–36, 136*t*, 139, 140
    - for drug dependence, 115, 116*t*, 117
    - for suicide, 177
  - Building Back Better* (WHO), 204
  - bullying, 150, 156, 189
  - buprenorphine maintenance, 57, 117, 118, 119, 226
  - burden of MNS disorders, 4–5*b*, 5–8, 22, 29–40. *See also* mortality rates
    - adult mental disorders, 67–68
    - alcohol use disorders, 32–34*t*, 128–30
    - childhood mental and developmental disorders, 146
    - depression, 69–70
    - Global Burden of Disease Study 2010 (GBD 2010), 29–30. *See also* Global Burden of Disease Study 2010
    - illicit drug dependence, 32, 32–34*t*, 34, 111, 118
    - implications of study findings, 36–37
    - limitations of study and directions for future research, 37–38
    - methodology of study, 30–31
    - neurological disorders, 87
    - overview, 29–30
  - Burundi, integration of mental health care into primary care program, 17*b*
- C**
- Canada
    - cost of Alzheimer’s disease treatment in, 98
    - fetal alcohol syndrome (FAS) warning labels in, 135
    - TEAMcare Canada, 213
  - cancer, 41, 48, 49, 56
  - cannabis dependence. *See also* illicit drug dependence
    - burden of disease, 32–34*t*
    - cannabis products, 109
    - deaths associated with, 7*t*, 110
    - estimated number of cause-specific and excess deaths for, 46*t*
    - medications for, 118
    - rates of dependence, 110
    - schizophrenia and, 53, 55*t*
  - cardiovascular disease, 48, 51, 52, 56, 213
  - Carroll, A. E., 150
  - case studies. *See also* Ethiopia; India
    - scaling up interventions for MNS disorders, 16–17*b*, 24
  - catastrophic financial effects, 2*b*
  - Cause of Death Ensemble Modeling (CODEm), 42
  - CBT. *See* cognitive behavioral therapy
  - Central/Eastern Europe and Central Asia
    - alcohol-related deaths in, 44, 55
    - cost-effectiveness of interventions in, 221, 227*t*
    - suicide of women in, 171
    - YLL rates in, 44, 45–46*f*, 55
  - child abuse, 68, 146, 148, 152
  - Child and Adolescent Mental Health Policies and Plans* (WHO), 148
  - childhood mental and developmental disorders, 145–61. *See also* attention-deficit hyperactivity disorder (ADHD); autistic spectrum disorders
    - anxiety disorders, 145, 146
    - bullying, 150, 156, 189
    - burden of disease, 146
    - consequences of, 146–47
    - cost-effectiveness of interventions, 155–56
    - epidemiology, 146
    - gender differences in, 5, 33, 146, 147*t*
    - interventions for, 9–10*t*, 12, 149–55, 149*b*, 156*t*
      - child and adolescent mental health policies and plans, 148
      - child protection legislation, 148–49
      - cognitive behavioral therapy (CBT), 153–55, 156
      - community platform interventions, 149–51
      - delivery platforms, 13*t*
      - early child development, 149–50
      - early intervention strategies, importance of, 36
      - health care platform interventions, 151–54
      - maternal mental health interventions, 152–53, 212
      - medications for ADHD, 154
      - medications for conduct disorder, 154
      - multisystem therapy, 155
      - parenting skills training, 152, 213–14
      - population platform interventions, 148–49
      - problem-solving skills therapy (PSST), 155
      - psychosocial treatments for conduct disorder, 154–55
      - school-based interventions, 150. *See also* education and schools
      - screening and community rehabilitation for developmental disorders, 151–52, 156
      - specialist health care, 154–55
      - Ten Questions screen, 151, 151*b*
      - voluntary sector programs, 150
    - nature of, 146
    - risk factors for, 146–48, 148*t*
    - trends, 148
    - types of, 145
  - Chile
    - CBT depression program in, 222



- National Depression Detection and Treatment Program, 16–17*b*, 213
- postpartum depression interventions in, 153, 207–8
- school-based interventions in, 192
- suicide rates in, 169
- China
  - alcohol consumption in, 129
  - taxation, 133
  - violence associated with, 129
- Central Government Support for the Local Management and Treatment of Severe Mental Illnesses Project, 16*b*
- depression, treatment of, 70
- drowning as premature cause of death in, 52
- headache interventions in, 102, 208, 228*b*
- suicide in, 164, 168, 170, 172, 175, 177
- survey of mental disorders in, 38
- Chisholm, D., 19, 232
- CHOosing Interventions that are Cost-Effective (CHOICE) project (WHO), 220, 226, 228, 228*b*, 232
- chronic or relapsing course, 1
- cocaine dependence. *See also* illicit drug dependence
  - age of death attributable to, 54*t*
  - burden of disease, 32–34*t*
  - consumption trends, 111
  - deaths associated with, 7*t*
  - estimated number of cause-specific and excess deaths for, 46*t*, 50*f*
  - pharmacotherapies
    - effectiveness for, 58
    - for psychostimulant dependence, 118
  - prevalence in North American and Latin America, 37
  - rates of dependence, 110
  - YLLs and, 43
- Cochrane Collaboration review, 207
- CODem (Cause of Death Ensemble Modeling), 42
- cognitive behavioral therapy (CBT)
  - for adult mental disorders, 76
  - for childhood mental and developmental disorders, 153–55, 156
  - for depression, 225
  - in adolescents, 222
  - for illicit drug dependence, 117
  - maternal and child health programs, 212
  - school-based, 192
  - workplace, 188, 189
- cognitive rehabilitation for dementia, 97, 213
- collaborative care models, 56, 77, 79, 207
- collaborative stepped care, 15, 77, 207–9, 213
- Colombia, cost-effectiveness analysis of antidepressants in, 225
- communicable compared to noncommunicable diseases in global burden of disease, 30, 36, 41
- community-based care
  - for childhood mental and developmental disorders, 151–52, 156
  - compared to hospital level of care, 228
  - for illicit drug dependence, 114–15, 116*t*
  - residential facilities, 15–16, 203
- community outreach teams, 16, 56, 77–78, 79
- community platform interventions, 13–14*t*, 15, 187–92, 194
  - adult mental health, 73–74
  - alcohol use disorders, 130–31, 135, 136*t*
  - childhood mental and developmental disorders, 149–51
  - gender equity and economic empowerment interventions, 193
  - identification and case detection, 193
  - illicit drug dependence, 113–14, 115*t*
  - neighborhood groups, 192–93, 194
  - parenting. *See* parenting interventions in schools. *See also* education and schools
  - suicide and, 175–76
  - treatment, care, and rehabilitation, 193
  - workplace. *See* workplace
- comparative risk assessments (CRAs), 6, 37, 42, 55*t*, 59
  - counterfactual burden and, 44, 53–56
- competency-based education, 209–10, 209*t*
- conduct disorders
  - burden of disease, 32–34*t*, 36
  - childhood, 145
  - deaths associated with, 7*t*
  - defined, 145
  - estimated number of cause-specific and excess deaths for, 46*t*, 49
  - interventions for, 9*t*
- contingency management approach to drug dependence, 117
- continuous quality improvement, 214
- Convention on the Rights of Persons with Disabilities, 215
- co-occurring disorders, 1, 8, 12, 47
  - alcohol use disorders and, 49
  - autistic spectrum disorders and, 48–49
  - bipolar disorders and, 48
  - dementia and, 52–53
  - epilepsy and, 52
  - integrating mental health into health programs for, 212–14
  - schizophrenia and, 48
- coping strategies and well-being, 172
- Corrigan, P. W., 187

- cost-effectiveness and affordability of interventions, 12, 18–19, 20*f*, 219–36
    - for adult mental disorders, 78
    - affordability, 229–31
      - alcohol use, demand reduction strategies for, 229, 229*f*
      - costs of scaling up, 232*f*
      - school-based social and emotional learning interventions, 229–30
    - of alcohol-related legislation, 221–22
    - for alcohol use disorders, 19, 20*f*, 137–38, 139–40, 221–22
    - for childhood mental and developmental disorders, 155–56
  - CHOosing Interventions that are Cost-Effective (CHOICE) project (WHO), 220, 226, 228, 228*b*, 232
  - collaborative care models, 56
  - community-based parenting programs, 222–23
    - for dementia, 98–99
  - economic evaluation of treatment and prevention, 18*b*
  - for epilepsy, 19, 20*f*, 58, 90, 93
  - extended cost-effectiveness analysis (ECEA), 19, 21*f*, 238
  - financial risk protection, 19
  - for headache disorders, 102
  - for illicit drug dependence, 118, 120
  - lack of evidence, 12–15, 21
  - limitation of conventional cost-effectiveness analysis, 220
  - for MNS disorders, 223–29
    - by country, 224*f*
    - international studies, 226
    - national studies, 224–26
    - primary health care, 224–27
  - nonspecialized treatment settings, 230–31
  - overview, 219–20
  - paucity of trials, 219, 222, 230
  - population and community levels, 220–23
  - school-based social and emotional learning interventions, 222, 229–30
  - specialist health care delivery, 228–29
  - costs of mental health care, 237–38
  - counseling sessions, 76
  - court-mandated treatment for drug dependence, 112*t*, 113
  - criminal activity related to illicit drugs, 111, 119
    - criminal justice platforms, 112*t*, 113
  - cross-border shopping for alcohol, 133
- D**
- DALYs. *See* disability-adjusted life years
  - DARE (Drug Abuse Resistance Education) program (US), 114
  - DART-AD (dementia antipsychotic withdrawal trial) trial, 53
  - decriminalization of suicide, 175
  - Degenhardt, L., 31
  - dementia, 93–99. *See also* Alzheimer's disease
    - age of death attributable to, 53, 54*t*
    - premature death, 41
    - age of onset, 8
    - burden of disease, 30, 32–34*t*, 87, 94–95, 94*f*, 95
    - caregiver stress, 95, 97
      - coping strategy program, cost-effectiveness of, 225
    - community health workers' detection abilities, 193
    - co-occurring disorders and, 52–53
    - cost-effectiveness of interventions for, 98–99
    - cost of, 8
    - definitions of, 31, 93–94
    - detection and diagnosis, 96
    - early-onset dementia, 94
    - epidemiology, 94–95
    - GBD findings of excess mortality for
      - estimated number of cause-specific and excess deaths, 46*t*, 51*f*, 52–53
      - implications, 58
    - interventions for, 10*t*, 96–98, 186
      - capacity of health care teams, 97–98
      - caregivers, 97
      - community-based programs, 98
      - health care delivery interventions, 97
      - integration into health care, 213
      - nonpharmacological interventions, 97
      - other interventions, 98–99
      - pharmacological interventions, 96–97, 98
      - specialist health care delivery, 15
    - recommendations for, 103
    - YLLs and, 43, 45*f*
  - dementia antipsychotic withdrawal trial (DART-AD) trial, 53
  - Dementia Society of Goa, 207
  - demographic factors, 3*b*
  - depression, 69–70. *See also* bipolar disorder; postpartum depression
    - age of cause-specific and excess deaths attributed to, 47*f*
    - alcohol use disorders and, 49–50
    - antidepressants, 56, 75*t*, 225, 226
    - burden of disease, 32, 32–34*t*, 34, 36
    - chronic illnesses associated with, 68
    - clinical features and course, 69
    - co-occurring disorders with, 47, 56, 69
    - cost-effectiveness of interventions for, 19, 20*f*, 227*t*, 230
      - antidepressants and CBT, 225, 226
      - enhanced financial and service coverage, 243–44

- DALYs associated with, 36
  - deaths associated with, 6, 7t
  - epidemiological surveys on, 38
  - epidemiology and burden of disease, 69–70
  - estimated number of cause-specific and excess deaths for, 46t, 47f, 49
  - gender differences, 68
  - interventions for, 8, 9t, 12, 75t
    - collaborative care, 207
    - electroconvulsive therapy (ECT), 74
    - European Alliance against Depression Programme, 176
    - limited access to, 12
    - primary health care, 13–14t, 15, 207–8
    - psychosocial interventions for adolescents, 190
    - self-care, 15
    - specialist health care delivery, 15
    - transcranial magnetic stimulation as treatment for, 74
  - serotonin-norepinephrine reuptake inhibitors (SNRIs) and, 225
  - suicide and, 69, 176
  - YLDs and, 68, 68f
  - YLLs and, 49
  - detoxification
    - alcohol use disorders, 136, 137t, 139
    - substance abuse, 116, 120
  - developed countries. *See* high-income countries (HICs)
  - developing countries. *See* low- and middle-income countries (LMICs)
  - developmental disorders, children with. *See* childhood mental and developmental disorders
  - developmental disorders, people with, 48. *See also* childhood mental and developmental disorders
  - diabetes, 41, 56, 128, 129, 184, 213
    - 3 Dimensions of Care for Diabetes (UK), 213
  - Diagnostic and Statistical Manual of Mental Disorders* (DSM), 31
    - DSM-4, 110, 208
    - DSM-5, 71–72, 110
  - disability-adjusted life years (DALYs)
    - alcohol use disorders and, 129
    - caused by MNS disorders, 5, 30–35, 31f, 32t, 34t
    - cost per DALY averted, 18, 19, 20f
    - gender differences, 32–33, 32t, 34–33, 34f, 34t
    - illicit drug dependence and, 36, 111
  - disasters and refugees, 177
  - Disease Control Priorities in Developing Countries*, 2b
  - DisMod-MR, 43, 47, 49, 59
  - disruptive behavioral disorders. *See* attention-deficit hyperactivity disorder (ADHD); conduct disorders
  - domestic violence legislation, 186
  - Dretzke, J., 155
  - driving impaired and traffic accidents, 49, 129, 137
    - cost-effectiveness of countermeasures, 221
    - countermeasures for, 134–35, 139
    - helmet laws, 186
  - Drug Abuse Resistance Education (DARE) program (US), 114
  - drug dependence. *See* illicit drug dependence
  - drug education, 114, 115t
  - drug testing
    - of offenders, 112t, 113
    - in workplace, 113–14, 115t
  - Drummond, M. F., 220
- E**
- early child development, 149–50, 192–93
  - early intervention
    - drug dependence of at-risk youth, 114
    - for psychosis treatment, 77
  - East Asia and Pacific
    - alcohol consumption in
      - cost-effectiveness of interventions, 137, 221
      - driver testing and arrest, 135
      - taxation, 133, 137
    - cost-effectiveness of interventions in, 227t, 239
    - suicide prevention organizations in, 176
    - suicide rates in, 164
    - traditional medicine in, 202
    - YLLs in, 44, 45–46f
  - Eastern Europe. *See* Central/Eastern Europe and Central Asia
  - Eastern Mediterranean Region
    - suicide in, 170
    - WHO proposed regional framework in, 23–24b
  - eating disorders, 3, 32–34t
  - ECEA. *See* extended cost-effectiveness analysis
  - economic effects
    - of illicit drug dependence, 111
    - of mental, neurological, and substance use (MNS) disorders, 8
  - economic evaluation of treatment and prevention, 18b. *See also* cost-effectiveness and affordability of interventions
  - ECT (electroconvulsive therapy), 74
  - education and schools
    - alcohol education campaigns, 139
    - early childhood enrichment programs, 192–93
    - epilepsy education, 58
    - illicit drug dependence
      - drug education, 114, 115t
      - skills training, 114, 115t
    - mental health awareness, 73–74
    - overdose prevention education, 114–15
    - peer-led education, 202
    - preschool educational programs, 192–93

- school-based interventions, 189–92, 194
    - alcohol use, 19, 139
    - childhood mental and developmental disorders, 150
    - emergency response, 190, 191*b*
    - HealthWise program (South Africa), 190, 190*b*
    - identification and case detection, 190–91
    - illicit drug dependence, 114, 115*t*
    - information and awareness, 189
    - Mental Health First Aid for High School Teachers, 191
    - social and emotional learning interventions, 189–90, 222, 229–30
    - suicide and self-harm, 176
    - teacher training program, 191*b*
    - treatment, care, and rehabilitation, 192
    - for vulnerable children, 190
    - whole-of-school approaches, 150
  - Egypt
    - childhood mental and developmental disorders, community-based interventions in, 149
    - suicide in, 170
  - Eickmann, S. H., 149
  - elderly persons. *See also* Alzheimer's disease
    - Home Care Program for (Goa), 207
    - neurological disorders in, 36
    - suicide rates of, 164
  - electroconvulsive therapy (ECT), 74
  - emergency response
    - drug-related interventions, 115
    - humanitarian aid, 16
    - mental health care, 204
    - school-based interventions, 190, 191*b*
  - environmental events, 3*b*
  - epilepsy, 88–93
    - alcohol use disorders and, 49
    - anti-epileptic drugs (AEDs), 88, 90, 91, 240
    - autistic spectrum disorders and, 48
    - birth trauma and, 185
    - burden of disease, 30, 32–34*t*, 87, 88–89
    - co-occurring disorders and, 52
    - cost-effectiveness of interventions for, 19, 20*f*, 58, 90, 93, 227*t*
      - extended cost-effectiveness analysis, 241*t*
    - DALY ranking of, 90
    - deaths associated with, 7*t*, 41
      - age of death, 53, 54*t*
    - definition of, 31, 88
    - epidemiology, 88–89
    - GBD findings of excess mortality for
      - estimated number of cause-specific and excess deaths, 46*t*, 51–52, 51*f*
      - implications, 58
    - gender differences in, 5, 33
    - interventions for, 8, 10*t*, 89–93
      - alternative therapies, 91
      - anti-stigma interventions, 89–90
      - helmet laws, 186
      - legislation, 90
      - management of infectious etiologies, 91
      - optimizing health care delivery, 91–92
      - pharmacological interventions, 58, 90–91
      - population platform interventions, 89
      - primary health care, 13–14*t*, 15
      - self-management, 90, 203
      - surgical management, 91, 93
      - treatment gap, 58, 92*f*, 93*b*
    - mental illness and, 52
    - recommendations for, 103
    - status epilepticus, 88
    - suicide and, 52
    - YLDs and, 90
    - YLLs and, 43–45, 45*f*
  - Ethiopia
    - alcohol use, demand reduction strategies for, 229
    - cost-effectiveness of interventions in, 18*b*
    - depression interventions in, 248*t*
      - productivity impact of scaled-up treatment, 246–47
    - extended cost-effectiveness analysis of publicly financed mental and neurological health care package in, 245–46, 247*t*
      - comparison with India, 249*t*
    - parenting skills training in, 152
    - school-based social and emotional learning intervention in, 230
  - European Alliance against Depression Programme, 176
  - European Headache Federation, 208
  - evidence-based interventions for health care delivery, 204, 205*t*
  - extended cost-effectiveness analysis (ECEA), 19, 21*f*, 238
    - application to MNS disorders, 238, 239
    - comparison of India and Ethiopia, 249*t*
    - Ethiopia analyses, 245–48
    - Indian analyses, 240–45
    - principles and practice, 238
- F**
- faith-based organizations, 202
  - family impacts and involvement, 1
    - alcoholics, family-based interventions for, 135, 139
    - family history of suicide, 170
    - illicit drug dependence, 110
    - in treatment, 74, 79
  - farmers, suicides of, 171

Farrington, D. P., 150  
 fetal alcohol syndrome disorders (FASD), 128, 135, 139  
 financial risk protection (FRP), 19, 203, 238, 239*b*  
 Finland  
   Alzheimer's disease, pharmacological interventions for, 98  
   epilepsy-related deaths in, 52  
   illicit drug use in, 111  
   workplace treatment, care, and rehabilitation in, 189  
 fluoxetine, 226  
 folic acid  
   deficiency, 94  
   food fortification, 185  
 forensic psychiatry, 203  
 fragile X syndrome, 48–49  
 France  
   APPRAND program, 188  
   fetal alcohol syndrome (FAS) warning labels in, 135  
 FRP (financial risk protection), 19, 203, 238, 239*b*  
 Fuhr, D., 19

**G**

gatekeeper training, 176, 223  
 GBD. *See* Global Burden of Disease Study 2010 (GBD 2010)  
 gender differences in burden of MNS disorders, 5,  
   32–34, 32*t*, 34*f*, 34*t*, 68  
   alcoholic consumption, 128–29  
   childhood mental and developmental disorders, 5,  
     33, 146, 147*t*  
   illicit drug dependence, 5, 45, 46*f*  
   suicide and, 164, 165*t*, 166–67*f*  
   YLLs and, 45, 46*f*  
 generic drugs. *See* medications  
 genotyping, 68  
 Global Burden of Disease Study 2010 (GBD 2010), 3,  
   29–30. *See also* burden of MNS disorders  
   comparative risk assessments. *See* comparative risk  
     assessments (CRAs)  
   excess mortality from MNS disorders, 41–65  
     assessment as risk factors for other health  
       outcomes, 44. *See also* co-occurring disorders  
     cause-specific death estimates, 42, 44–53. *See also*  
       *specific MNS disorders*  
     implications, 56–58  
     methodology of study, 42–44. *See also* years of life  
       lost (YLLs)  
   transition from communicable to  
     noncommunicable diseases, 30, 36, 41  
 Global Burden of Disease Study 2013 (GBD 2013), 38  
 Global Campaign against Headache, 101  
 Global Campaign against Headache for Europe,  
   102, 208

Global Health Estimates of disease burden, 5  
 globalization of alcohol beverages industry, 128  
 Gmel, G., 133  
 Good Behavior Game (US), 114  
 good practice interventions, 12, 15, 183, 184*t*, 188,  
   193, 214  
 Grading of Recommendations Assessment,  
   Development and Evaluation (GRADE)  
   guidelines, 8, 130–31  
 Gunnell, D., 17*b*

**H**

Handwerk, M., 155  
 Happell, B., 56  
 HCV (hepatitis C), 51, 57, 111, 119  
 headache disorders, 99–102. *See also* migraine  
   burden of disease, 100  
   cost-effectiveness of interventions for, 102  
   epidemiology, 100  
   interventions for, 100–101, 188  
     alternative therapies, 101  
     optimizing health care delivery, 102, 208  
     pharmacological interventions, 100–101  
     public education programs, 101–2  
     self-management, 100  
     training health care providers, 102  
   medication-overuse headache, 99–100  
   recommendations for, 103  
   tension-type headache, 99  
 Headache Management Trial, 208  
 health care platform interventions, 4*b*, 13–14*t*, 15–16,  
   201–18  
   for alcohol use disorders, 135–37. *See also* alcohol  
     use disorders  
   for childhood mental and developmental disorders,  
     151–54. *See also* childhood mental and  
     developmental disorders  
   collaborative stepped care. *See* collaborative  
     stepped care  
   for depression, 70  
   elements of, 201–4  
   emergency mental health care, 204. *See also*  
     emergency response  
   evidence-based, 204  
   hospital level of care, 13–14*t*, 15, 203  
   for illicit drug dependence, 114–18, 116*t*. *See also*  
     illicit drug dependence  
   integrating mental health into existing health  
     programs, 212–14  
   for mood and psychotic disorders, 74–78  
   primary level. *See* primary health care level  
 Programme for Improving Mental health care  
 (PRIME), 209, 231

- for psychiatric services, 203
  - quality of care, 15, 214–15
  - relationships among difference delivery channels, 204
  - self-care and informal health care, 202–3. *See also* self-care
  - specialists. *See also* specialist health care delivery training primary health care staff by, 210
  - for suicide, 177–78
  - system-strengthening strategies for, 204–9
  - task-sharing approach, 209–12, 210*b*
  - Healthnet Transcultural Psychosocial Organization (TPO), 17*b*
  - HealthWise program (South Africa), 190, 190*b*
  - hepatitis B, 51, 111
  - hepatitis C (HCV), 51, 57, 111, 119
  - heroin. *See* illicit drug dependence; opioid dependence
  - high-income countries (HICs). *See also specific countries*
    - alcoholic consumption in, 128, 138
    - burden of MNS disorders in, 5, 29
    - cost-effectiveness of interventions in, 19
      - drug dependence treatments and interventions, 118
    - dementia care costs in, 95*f*
    - epilepsy-related deaths in, 51
    - intervention delivery platforms in, 12
    - screening children for developmental disorders, 151–52
    - specialist services, 2
  - Hip Hop Stroke (awareness program for children), 189
  - HIV/AIDS
    - alcohol use and, 184
    - anti-epileptic drugs for people with, 91
    - burden of disease, 57
    - cost-effective prevention strategy, 226
    - dementia and, 94
    - illicit drug use and, 51, 58, 110–11, 115, 119
    - integrating mental health into existing programs for, 212
    - mental health needs of persons with, 213–14
    - methadone maintenance and, 117, 118
    - suicide and, 169
  - HIV antiretroviral therapy, 57
  - home care programs, 207
  - Honduras, epilepsy treatment in, 89, 186
  - hospital level of care, 13–14*t*, 15, 203
    - cost-effectiveness of, 228–29
  - humanitarian aid and emergency response, 16, 204
  - human rights violations, 58, 67, 214, 215
- I**
- ibuprofen, 100
  - ICD-10. *See* International Classification of Diseases
  - illicit drug dependence, 109–25. *See also* amphetamine dependence; cannabis dependence; cocaine dependence; opioid dependence
    - age of death attributable to, 54*t*
    - burden of disease, 32, 32–34*t*, 34, 111, 118
    - consequences, 110–11
    - consumption trends, 111
    - cost-effectiveness of interventions, 118, 120
    - criminal activity, 111, 119
    - DALYs associated with, 36, 111
    - definition of, 31, 109–10, 120*n*1
    - delivery platforms for, 14*t*
    - economic costs of, 111
    - externalizing disorders, 114, 120*n*4
    - family factors, 110
    - GBD findings of excess mortality for
      - estimated number of cause-specific and excess deaths, 49, 50*f*, 51
      - implications of, 57–58
    - gender differences in, 5, 45, 46*f*
    - global trends, 111
    - implications for low- and middle-income countries, 118–19
    - individual factors, 110
    - injecting drug risks, 51, 53, 55*t*, 57, 226
    - internalizing disorders, 114, 120*n*4
    - interventions and policies, 11*t*, 111–18
      - access to treatment, 114
      - brief psychological intervention, 115, 116*t*, 117
      - cognitive behavioral therapy (CBT), 117
      - community-based care, 114–15, 116*t*
      - community platform interventions, 113–14, 115*t*
      - contingency management approach, 117
      - control of supply, 112
      - court-mandated treatment, 112*t*, 113
      - criminal justice platforms, 113
      - delivery platforms for, 14*t*
      - detoxification and withdrawal, 116, 120
      - drug education, 114, 115*t*
      - drug testing of offenders, 112*t*, 113
      - early intervention with at-risk youth, 114
      - health care platform interventions, 114–18, 116*t*
      - imprisonment, 112*t*, 113, 120
      - law enforcement, 112, 112*t*, 119–20
      - legislation, 186
      - medication for cannabis dependence, 118
      - medication for heroin and opioid dependence, 116*t*, 117
      - naloxone and other emergency responses, 115
      - overdose prevention education, 114–15
      - population platform interventions, 112–13, 112*t*
      - prescription monitoring programs, 112–13, 112*t*
      - primary health care, 13–14*t*, 15, 115, 116*t*

- psychosocial interventions, 117
- public awareness campaigns, 112*t*, 113
- residential rehabilitation, 117
- school-based prevention programs, 114, 115*t*
- self-help and mutual aid groups, 114, 115*t*
- skills training in schools, 114, 115*t*
- specialist health care delivery, 15, 116–17, 116*t*
- supervised injecting facilities, 57, 115
- therapeutic community (TC) model, 117
- workplace drug testing, 113–14, 115*t*
- medical vs. moral models of addiction, 12, 119
- mortality rates, 110–11
- narcotic antagonists, 119, 120, 120*n6*. *See also*
  - buprenorphine maintenance; naltrexone maintenance
- natural history of dependence, 110
- novel psychoactive substances, 109, 120*n2*
- peer group factors, 110
- pharmacotherapies, effectiveness of, 57–58
- polydrug use, 114, 120*n5*
- precursor chemicals, 112, 112*t*, 120*n3*
- recommendations, 119–20
- research needs, 119, 120
- risk factors, 110
- social and contextual factors, 110
- suicide and, 51, 55*t*, 110, 175
- YLLs and, 45*f*, 53, 110
  - gender differences and, 45, 46*f*
- imprisonment for drug offenses, 112*t*, 113, 120
- India
  - alcohol consumption in, 129
    - demand reduction strategies for, 229
    - taxation on, 133
    - unrecorded production and consumption, 221
  - collaborative care for mental illnesses in, 77
  - community-based rehabilitation in, 78
  - cost-effectiveness of interventions in, 18*b*
    - depression, 230, 243–44, 244*t*
    - extended analysis for schizophrenia, 19, 21*f*
  - Dementia Society of Goa, 207
  - District Mental Health Programme, 208
  - education and schools in
    - examination stress, 175
    - teacher training for youth health promotion program, 222
    - teacher training to improve epilepsy knowledge, 191
  - epilepsy interventions in, 240, 241*t*
  - extended cost-effectiveness analysis (ECEA), 240–45
    - comparison with Ethiopia, 249*t*
  - headache interventions in, 228*b*
  - MANAS (MANashanti Sudhar Shodh, or project to promote mental health), 78, 207, 224–25
  - maternal and infant health programs in, 153
  - National Sample Survey Organization, 238
  - pesticide ban in, 185
  - school-based social and emotional learning
    - intervention in, 230
  - suicide in, 168, 170, 178
    - religious and spiritual beliefs, 172
    - safe storage of pesticides, 176
    - universal health coverage, 240, 245*f*
- indigenous communities and alcohol consumption
  - community platform interventions, 135, 136*t*
  - prohibition, 131, 131*t*
- individual factors
  - alcohol use disorders, 130
  - illicit drug dependence, 110
- infants
  - immunization programs for, 185
  - maternal and infant health programs, 153
  - psychosocial interventions for, 149, 150
  - salt iodization programs for, 185
- informal health care. *See* self-care
- information and communication packages, 78
- injecting drug risks, 51, 53, 55*t*, 57, 226
- Institute for Health Metrics and Evaluation at University of Washington, 38
- Institute of Medicine's Forum on Neuroscience and Nervous System Disorders, 209
- intellectual disability
  - burden of disease, 32–34*t*
  - childhood, 145
  - defined, 145
  - effective interventions for, 10*t*
- Inter-Agency Standing Committee's *Guidelines on Mental Health and Psychosocial Support in Emergency Settings*, 204
- International Classification of Diseases (ICD-10), 5, 31, 35, 37, 42, 46, 49, 72, 109, 168
- International Convention on the Rights of Persons with Disabilities, 186
- International Labour Organization, 188
- International League against Epilepsy, 88
- interventions for MNS disorders, 8–12
  - for adult mental disorders, 73–78. *See also* adult mental disorders
  - for alcohol use disorders, 130–37. *See also* alcohol use disorders
  - case studies, 16–17*b*
  - for childhood mental and developmental disorders, 149–55. *See also* childhood mental and developmental disorders
  - collaborative care models, 56
  - community-based. *See* community platform interventions

- costs. *See* cost-effectiveness and affordability of interventions
  - delivery platforms of, 12–17, 13–14*t*
  - for dementia, 96–98
  - effective essential interventions, 8–12, 9–11*t*
  - health care. *See* health care platform interventions
  - for illicit drug dependence, 11*t*, 111–18. *See also* illicit drug dependence
  - limited access to, 12
  - population-based. *See* population platform interventions
  - quality of care, 15, 214–15
  - iodine deficiency, 185
  - Iran, suicide in, 176, 177
  - Israel
    - community-based interventions for childhood mental and developmental disorders, 149
    - Heart Disease study, 52
- J**
- Jamaica
    - childhood emotional and behavioral problems in, 150
    - psychosocial interventions for malnourished infants in, 149, 150
- K**
- Kamgno, J., 52
  - Kenya
    - epilepsy-related deaths in, 52, 88
    - epilepsy treatment in, 89
    - training of primary care workers in, 210
  - ketogenic diet, 91
  - key messages, 4*b*
  - Kilian, R., 155
  - knowledge gaps, effect on scaling up, 21–22
  - Korea, Republic of
    - dementia detection program in, 98
    - suicide in, 175
- L**
- Lachenmeier, D., 133–34
  - Latin America and the Caribbean
    - alcohol consumption in, 129
      - cost-effectiveness of interventions, 137, 221
      - partial bans on, 132
      - self-help and support groups, 136, 137
      - taxation on, 132–33
    - cost-effectiveness of interventions in, 221, 226, 227*t*
    - substance use disorders in, 44
    - suicide in
      - religious and spiritual beliefs, 172
      - risk factors, 169
      - survivors of suicide loss, 172
      - traditional medicine in, 202
      - YLLs in, 44, 45–46*f*
  - law enforcement
    - alcohol use disorders and, 132*t*
    - illicit drug dependence and, 112, 112*t*, 119–20
  - legislation
    - on alcoholic beverages, 221–22
    - child protection legislation, 148–49
    - on epilepsy, 90
    - illicit drugs legislation, 186
    - mental health legislation, 73
    - restricting access to lethal means of suicide, 17*b*, 176, 185, 194, 222
  - licensing of alcoholic beverages sellers, 138
  - life expectancy gap in people with mental disorders, 41, 42, 57. *See also* years of life lost (YLLs)
  - lifestyle risk factors, 47, 56–57, 58, 101
  - Lim, S. S., 44, 129
  - List of Essential Medicines* (WHO), 57
  - liver cirrhosis, 50, 184
  - low- and middle-income countries (LMICs). *See also specific countries*
    - alcohol consumption in, 128
      - challenges for, 138–39
      - cost-effective interventions, 221
      - mortality rates associated with, 130
      - recommendations for, 139
    - burden of MNS disorders in, 29
    - cause-of-death data from, 58
    - childhood mental and developmental disorders,
      - community-based interventions in, 149
    - dementia care costs in, 95*f*
    - epilepsy-related deaths in, 51
    - epilepsy treatment gap in, 58, 92*f*
    - illegal substance dependence in
      - assessment issues, 118
      - burden of disease, 118
      - cost-effectiveness of interventions, 118
      - health care infrastructure and capacity, 119
      - implications, 118–19
      - medical vs. moral models of addiction, 119
      - opioid substitution treatment (OST), 57, 119
      - potential new treatments, 119
      - research needs, 119
    - intervention delivery platforms in, 12, 29
    - MNS disorders in, 5
    - mood and anxiety disorders in, 69
    - neurological disorders in, 87
    - suicide surveillance in, 168
    - survey of mental disorders in, 38
    - transition from communicable to noncommunicable diseases in, 41
    - vital registration systems, lack of, 163
  - lung cancer, 42



## M

- major depressive disorder. *See* depression
  - Malaysia, suicide in, 175, 177
  - MANAS (MANashanti Sudhar Shodh, mental health project in India), 78, 207, 224–25
  - mania, 69, 71. *See also* bipolar disorder
  - mass media campaigns. *See* public awareness campaigns
  - maternal depression. *See* postpartum depression
  - maternal mental health interventions, 152–53, 212
  - Mauritius
    - preschool program in, 150
    - school-based prevention program for adolescent depression in, 222, 229
    - school-based social and emotional learning intervention in, 230
  - Maximizing Independence at Home project, 97
  - media reporting of suicide and self-harm, 175
  - medical marijuana, 91
  - medical vs. moral models of addiction, 12, 119
  - medications
    - access of people with mental disorders to, 48
    - for ADHD, 154
    - antipsychotics for dementia patients, 53, 96–97
    - for conduct disorder, 154
    - cost-effectiveness of, 226
    - for epilepsy. *See* anti-epileptic drugs (AEDs)
    - low-cost generics, 22, 226
    - morbidity and mortality rates related to treatment with, 47
    - pharmacotherapies
      - for dementia, 96–97, 98
      - for epilepsy, 90–91
      - for headache disorders, 100–101
      - for heroin and opioid dependence, 116*t*, 117
      - for mood and psychotic disorders, 74, 75–76*t*, 79
      - for substance use disorders, 48, 57–58, 118
    - prescription monitoring programs, 112–13, 112*t*
    - psychotropic medications
      - effects of, 48, 56
      - primary care staff prescribing, 212
  - Megiddo, I., 240
  - memantine, 96, 98
  - men. *See* gender differences
  - mental, neurological, and substance use (MNS) disorders, 1, 2. *See also* neurological disorders; *specific types of disorders*
  - adults. *See* adult mental disorders
  - alcohol abuse. *See* alcohol use disorders
  - children. *See* childhood mental and developmental disorders
  - disability-adjusted life years (DALYs) due to, 5. *See also* disability-adjusted life years
  - economic output lost due to, 8
  - mortality rates associated with, 6. *See also* mortality rates
  - need for action to address, 22–23
  - significance for global health, 5–8
  - substance abuse. *See* illicit drug dependence
  - years lived with disability (YLDs) and, 5, 6*f*. *See also* years lived with disability
  - years of life lost (YLLs) and, 5, 6, 6*f*. *See also* years of life lost
- mental disorders. *See* adult mental disorders; childhood mental and developmental disorders; mental, neurological, and substance use (MNS) disorders; *specific disorders (e.g., anxiety, depression)*
  - mental health awareness campaigns, 73, 186–87. *See also* public awareness campaigns
  - mental health first aid training, 188, 191, 193, 223
  - Mental Health Gap Action Programme (mhGAP). *See* World Health Organization (WHO)
  - mental health legislation, 73. *See also* legislation
  - mental health workers
    - health centers or home visitation programs using, 193
    - human resource competencies for MNS disorders in, 210
    - low availability of, 12
    - pre-service and in-service training of primary care workers, 210
  - methadone maintenance, 57, 111, 113, 117, 118, 226
  - Mexico
    - alcoholic beverages in
      - cost-effectiveness of interventions, 138
      - demand reduction strategies for, 229
      - unrecorded production of, 133
    - illicit substance use in, 111
    - school-based social and emotional learning intervention in, 230
  - mhGAP. *See* World Health Organization
  - microfinance, 193
  - Middle East and North Africa
    - cost-effectiveness of interventions in, 227*t*
    - illicit drug dependence in, 44
    - suicide of women in, 171
  - midwives, role of, 212
  - migraine. *See also* headache disorders
    - burden of disease, 32–34*t*, 87
    - cost-effectiveness of interventions for, 228*b*
    - DALYs associated with, 36
    - deaths associated with, 7*t*
    - definition of, 99
    - estimated number of cause-specific and excess deaths for, 46*t*
    - interventions for, 10*t*, 188
    - primary health care, 13–14*t*, 15
    - self-care, 15

Mihalopoulos, C., 155, 223  
 Millennium Development Goals, 214  
 Mini-Mental State Examination, 96  
 MNS. *See* mental, neurological, and substance use (MNS) disorders  
 monitoring and evaluation of interventions, 22  
 monitoring and reporting systems  
   dementia, 213  
   suicide and self-harm, 177  
 mood disorders, 68–70, 75*t*. *See also* anxiety disorders; depression  
 moral vs. medical model of addiction, 12, 119  
 morphine maintenance, 117  
 mortality rates. *See also* Global Burden of Disease Study 2010 (GBD 2010); years of life lost (YLLs)  
   for alcohol use disorders, 7*t*, 44, 129  
   cause-of-death data, difficulty in capturing, 58–59  
   illicit drug dependence, 110–11  
   MNS disorders associated with, 6–7, 7*t*, 22, 41  
   models used in estimating, 43, 43*f*  
   suicide mortality rates, 164, 165*t*  
 multiple sclerosis, 3, 29, 32–34*t*, 87  
 multisystem therapy, 155  
 music therapy, 74  
 mutual aid groups. *See* support groups

## N

naloxone and other emergency responses, 115  
 naltrexone maintenance, 57, 117, 119  
 narcotics. *See* illicit drug dependence  
 National Institute for Health and Care Excellence (NICE), 99  
 natural history models, 43, 45–46, 48, 49, 59  
 needle programs, 57  
 neighborhood factors, 3*b*  
 neighborhood groups, 192–93, 194. *See also* self-help programs; support groups  
 neurocysticercosis, 89*b*, 91, 186  
 neurological disorders, 87–108. *See also* epilepsy; headache disorders  
   burden of disease, 30, 32–34*t*, 87  
   community health workers' detection abilities, 193  
   cost-effectiveness of interventions for, 226  
   in elderly persons, 36  
   GBD findings of excess mortality for  
   estimated number of cause-specific and excess deaths, 46*t*, 51, 51*f*  
   implications, 58  
   gender differences in, 45, 46*f*  
   interventions for, 10*t*  
   delivery platforms, 14*t*  
   school-based interventions, 189, 192

YLDs and, 87  
 YLLs and  
   gender differences and, 45, 46*f*  
   regional differences and, 55  
 New Zealand  
   fetal alcohol syndrome (FAS) warning labels in, 135  
   indigenous communities, alcohol consumption by, 135  
 Nigeria  
   alcohol use, demand reduction strategies for, 229  
   community-based awareness in, 73  
   depression in, 69, 70, 208, 225  
   epilepsy in, 230  
   schizophrenia in, 225, 230  
   suicide in, 169  
 noncommunicable diseases  
   compared to communicable diseases in global burden of disease, 30, 36, 41  
   integrating mental health into primary care for, 213  
 nonspecialist human resource cadres, 15, 22  
 Norwegian dementia mortality study, 52  
 novel psychoactive substances, 109, 120*n2*

## O

obesity, 49, 56–57, 100  
 obsessive-compulsive disorder (OCD), 70  
 occupational therapy, 76, 79  
 Open the Doors program, 187  
 opioid dependence. *See also* illicit drug dependence  
   burden of disease, 32–34*t*  
   consumption trends, 111  
   DALYs associated with, 36  
   deaths associated with, 7*t*, 37, 41  
   age of death, 54*t*  
   GBD findings of excess mortality for  
   estimated number of cause-specific and excess deaths, 46*t*, 50*f*, 51  
   implications, 57–58  
   illicit opioids, 109  
   naltrexone maintenance, 117  
   opioid substitution treatment (OST), 57, 113, 114, 118, 119, 120. *See also* methadone maintenance  
   prevalence in Australasia and Western Europe, 37  
   rates of dependence, 110  
   substance use disorders and, 51  
   supervised injectable heroin maintenance, 57, 117  
   YLLs and, 37, 43  
 overdose prevention education, 114–15  
 oxycodone, 111. *See also* opioid dependence

## P

Pakistan  
   depressive disorder related to suicide in, 169

- mental health awareness among school children in, 74
- preventive maternal and child health care in, 153
- rural secondary schools in, 189
- suicide in, 175
  - depressive disorder related to, 169
  - women, 171
- Thinking Healthy Programme, 212
- Palestine, school-based intervention in, 191*b*
- panic disorder, 70, 75*t*
- parenting interventions, 193
  - community-based program for, cost-effectiveness of, 222–23
  - skills training, 152, 213–14
- Parkinson's disease
  - burden of disease, 30, 32–34*t*, 87
  - gender differences in, 5, 33
- peer-led interventions
  - education, 202
  - illicit drug dependence, 110
  - self-help groups and peer support, 203
- Perinatal Mental Health Project (South Africa), 212
- pesticides
  - regulation to restrict access to, 17*b*, 176, 185
  - safe storage of, 176
  - self-poisoning, 175, 177
- Phanthunane, P., T. Vos, 225
- pharmacologic treatment. *See* medications
- phobias, 70
- Pion, S. D. S., 52
- Plan Do Study Act, 214
- Platania-Phung, C., 56
- pneumonia, 53, 56
- political will, effect on scaling up, 21
- polydrug use, 114, 120*n*5
- Pompili, P., 52
- population platform interventions, 13–14*t*, 15, 183–87, 193–94
  - for adult mental health, 73
  - for alcohol use disorders, 130, 131–35, 131*t*
  - for childhood mental and developmental disorders, 148–49
  - for epilepsy, 89
  - for illicit drug dependence, 112–13, 112*t*
  - information and awareness campaigns, 186–87
  - key findings, 183
  - legislation and regulations, 184–85. *See also* legislation
  - protecting persons with MNS disorders, 186
  - restricting access to means of suicide, 185
  - for suicide, 174–75
- postpartum depression, 75*t*, 77, 152–53, 212
  - women's support groups for, 153
- post-traumatic stress disorder (PTSD), 49, 68, 70, 75*t*, 77, 192
- poverty. *See also* financial risk protection (FRP)
  - microfinance schemes and, 193, 221
  - schizophrenia and, 48
  - suicide and, 169, 170, 175
- Powell, C., 149
- precursor chemicals, 112, 112*t*, 120*n*3
- pregnancy
  - alcohol use in, 135, 139
  - vulnerability for MNS disorders, 185
- premature mortality, 5. *See also* years of life lost (YLLs)
  - Preventing Suicide: A Global Imperative* (WHO), 177
- prevention of MNS disorders, 4*b*, 8–12, 9–11*t*. *See also*
  - interventions for MNS disorders
  - adult mental disorders, 76–77
  - cost-effectiveness of. *See* cost-effectiveness and affordability of interventions
- primary health care level, 13–14*t*, 15, 203
  - for alcohol use disorders, 13–14*t*, 15
  - competency-based education, 209–10, 209*t*
  - cost-effectiveness of, 224–27
    - international studies, 226
    - national studies, 224–26
  - evidence-based, 205*t*
  - for illicit drug dependence, 13–14*t*, 15, 115
  - planning and consultation, 210
  - pre-service and in-service training of workers, 210
  - psychotropic medications, prescription authority for, 212
- Prince, M., 44
- problem-solving skills therapy (PSST), 155
- PRogramme for Improving Mental health carE (PRIME), 209, 231
- psychiatric services, 203. *See also* specialist health care delivery
- psychosis, 2
  - extended cost-effectiveness analysis for, 19
  - interventions for, 8
  - medications for, 226
  - primary health care for, 13–14*t*, 15
  - specialist health care delivery for, 15
- psychosocial interventions
  - for conduct disorder, 154–55
  - for illicit drug dependence, 117
  - for malnourished infants, 149
- psychosocial life crises and suicide, 169–70
- psychotherapy for mood and psychotic disorders, 74, 75–76*t*
- psychotropic medications, effects of, 48, 56
- PTSD. *See* post-traumatic stress disorder

- public awareness campaigns, 186–87, 194
  - alcohol consumption, 135
  - headaches, 101, 102
  - illicit drug dependence, 112*t*, 113
  - mental health, 73
- Public Health Action for the Prevention of Suicide* (WHO), 177
- public health considerations
  - alcohol use disorders, 128
  - health platform related, 208
  - integrating mental health into existing programs, 212–14
  - maternal mental health, 153
  - suicide, 173
- Q**
- quality-adjusted life years (QALYs), 155, 225
- quality of care, 15, 214–15. *See also* health care platform interventions
- R**
- RAP-A program, 230, 230*t*
- refugees, suicides of, 171–72, 177
- rehabilitation
  - cognitive rehabilitation for dementia, 97
  - illicit drug dependence, 117
  - mental disorders, 78
- Rehm, J., 133–34, 137, 221
- relaxation techniques, 74
- religious beliefs and suicide, 172
- religious healers, 202
- research and development initiatives, 22
  - for illicit drug dependence, 119, 120
- residential facilities, 15–16, 203
  - for illicit drug dependence interventions, 117
- Resourceful Adolescent Programme-Adolescent version (RAP-A) program, 229–30, 230*t*
- respiratory diseases, 41, 56
- risk factors
  - for childhood mental and developmental disorders, 146–48, 148*t*
  - for illicit drug dependence, 110
  - for suicide, 37, 168–71, 173*f*, 178
- risperidone, 226
- Russian Federation, headache interventions in, 102, 208, 228*b*
- S**
- Saxena, S., 232
- scaling up, 4–5*b*
  - affordability and. *See* cost-effectiveness and affordability of interventions
  - case studies of interventions for MNS disorders, 16–17*b*
  - extended cost-effectiveness analysis for, 19, 21*f*
  - health system barriers and opportunities for, 21–22
  - knowledge gaps as factors, 21–22
  - political will as factor, 21
  - proposed regional framework in WHO Eastern Mediterranean Region, 23–24*b*
  - strategies for strengthening health system, 22
- schizophrenia, 72–73
  - age of cause-specific and excess deaths attributed to, 47*f*
  - burden of disease, 32–34*t*
  - cannabis dependence and, 53, 55*t*
  - clinical features and course, 72
  - co-occurring disorders with, 48
  - cost-effectiveness of interventions for, 19, 20–21*f*, 225, 227*t*, 230
    - community-based vs. hospital-based services, 228
    - extended cost-effectiveness analysis, 242*t*
  - DALYs associated with, 36
  - deaths associated with, 7*t*
    - age of death, 54*t*
  - environmental factors associated with, 68
  - epidemiology and burden of disease, 72–73
  - estimated number of cause-specific and excess deaths for, 46–48, 46*t*, 47*f*
  - extended cost-effectiveness analysis for, 19, 21*f*, 241–45
  - gender differences in, 5, 33, 68
  - genotyping of individuals with, 68
  - interventions for. *See also* adult mental disorders
    - enhanced financial and service coverage, 241–43
    - pharmacologic and psychological treatment, 76*t*
  - side effects of antipsychotic medications for, 48
  - suicide and self-harm and, 48
  - YLDs and, 68, 68*f*
  - YLLs and, 43, 45*f*, 48
- schools. *See* education and schools
- Scott, D., 56
- screenings
  - for alcohol use disorders, 135–36, 136*t*, 139
  - for childhood mental and developmental disorders, 151–52, 156
  - for comorbid health issues, 56–57
  - for dementia, 98
  - for illicit drug dependence, 115, 117
  - for mental health disorders, 77
- SDG (sustainable development goal), 2*b*
- self-care, 13–14*t*, 15, 202–3
  - for epilepsy, 90
  - evidence-based, 205*t*
  - for headache disorders, 100
  - for mood and psychotic disorders, 74

- self-harm. *See* suicide and self-harm
- self-help programs, 57, 202–3  
 for alcohol use disorders, 136–37  
 for illicit drug dependence, 114, 115*t*
- self-immolation. *See* suicide and self-harm
- serotonin-norepinephrine reuptake inhibitors (SNRIs), 225
- Service Organization Pyramid for an Optimal Mix of Services for Mental Health* (WHO), 202, 202*f*
- sexual minorities, suicide of, 172
- shame and fear, 67
- SHR (sustained headache relief), 100
- simple phobias, 70
- Single Convention on Narcotic Drugs, 120*n*1
- Six Sigma, 214
- Skeen, S., 194
- smoking, 47–48, 49, 52, 56–57
- Sneha (suicide prevention organization), 175
- sobriety checkpoints, 134
- social anxiety disorder, 70
- social causation pathway, 3*b*
- social change, 3*b*
- social determinants, 1, 3*b*  
 for illicit drug dependence, 110
- social drift pathway, 3*b*
- societal response to alcohol use disorders, 130
- socioeconomic status, 3*b*. *See also* poverty  
 drinking and, 129  
 schizophrenia and, 48
- SOLVE training package, 188
- Sornpaisarn, B., 133
- South Africa  
 alcohol consumption of pregnant women in, 135  
 collaborative stepped care approach in, 210  
 epilepsy treatment in, 89  
 HealthWise program in, 190, 190*b*  
 HIV/AIDS treatment integrated with mental health in, 214  
 parenting skills training in, 152  
 Perinatal Mental Health Project, 212  
 Primary Care 101 (PC101), 214  
 primary care practitioners in, 208  
 workplace interventions in, 189
- South Asia  
 alcohol consumption in  
 cost-effectiveness of interventions, 137, 221  
 taxation, 133, 137  
 cost-effectiveness of interventions in, 226, 227*t*, 231, 239  
 suicide prevention organizations in, 176  
 suicide rates in, 164  
 traditional medicine in, 202
- specialist health care delivery, 15, 74–76, 203  
 for alcohol use disorders, 15  
 for childhood mental and developmental disorders, 154–55  
 cost-effectiveness of, 228–29  
 evidence-based, 205*t*  
 for extended-stay facilities, 203  
 for illicit drug dependence, 15, 116–17, 116*t*
- Sri Lanka  
 children with developmental delays in, 151  
 suicide in, 170, 171, 175, 177–78  
 prevention through pesticide regulation, 17*b*, 185, 185*b*  
 safe storage of pesticides, 176
- START (STrategies for RelaTives) study, 99
- Statistical Process Control, 214
- stigma and discrimination, 1, 5*b*, 22, 67  
 anti-stigma interventions, 89–90, 187  
 limiting access to interventions, 12  
 limiting access to screenings, 56  
 quality of care and, 214  
 self-care and, 203  
 suicide and, 175, 176
- Strang, J., 8
- stroke, 41, 56
- Sub-Saharan Africa  
 alcohol consumption in, 129  
 cost-effectiveness of interventions, 137, 221  
 mortality associated with, 129  
 taxation, 133, 137  
 childhood mental disabilities, lack of data on, 146  
 cost-effectiveness of interventions in, 221, 226, 227*t*, 231, 239  
 epilepsy in, 44, 45, 52, 89, 91  
 human resource competencies for MNS disorders in, 210  
 illicit drug dependence in, 44  
 cost-effectiveness of interventions, 118  
 microfinance in, 193  
 traditional medicine in, 202  
 YLL rates in, 44, 45–46*f*, 55  
 gender differences and, 45, 46*f*
- substance use disorders. *See* illicit drug dependence
- suicide and self-harm, 42, 163–81  
 of adolescents, 171  
 age pattern of, 164, 165*t*, 166–67*f*  
 alcohol consumption and, 50, 129, 169, 175  
 as cause of death, 41, 164  
 changes in rates (2000–12), 164, 165*t*  
 coping strategies and well-being, 172  
 cost-effectiveness of prevention efforts, 178  
 decriminalization of, 175  
 definition of, 163

- depression and, 69, 176
  - drug misuse and, 175
  - early traumatic events associated with, 170–71
  - economic issues and, 175
  - effective interventions for, 11*t*
  - epidemiology, 163
  - epilepsy and, 52
  - exposure to models, 170
  - family history of suicide, 170
  - of farmers, 171
  - gender differences, 164, 165*t*, 166–67*f*, 171
  - interventions for, 11*t*, 174–78
    - brief intervention and contact, 177
    - community platform interventions, 175–76
    - delivery platforms, 14*t*
    - disasters and refugees, 177
    - examination stress, 175
    - gatekeeper training, 176
    - health care platform interventions, 177–78
    - medical management of poisoning with pesticides, 177
    - monitoring and reporting systems, 177
    - national suicide prevention strategies, 177–78
    - nongovernmental organization services, 175–76
    - population platform interventions, 174–75, 194
    - restricting access to lethal means, 17*b*, 174–75, 176, 185, 194, 222
    - safe storage of pesticides, 176
    - school-based interventions, 176
    - stigma and discrimination, 175
  - media reporting of, 175
  - mental disorders and alcohol misuse associated with, 169
  - methods, availability of, 168, 170
  - pesticide self-poisoning, 175, 177
    - Sri Lanka suicide prevention through pesticide regulation, 17*b*, 185*b*
  - physical disorders and, 169
  - prevention in LMICs, 172–74
  - prior suicide attempts, 170
  - protective factors, 172
  - psychosocial life crises and, 169–70
  - as public health issue, 173
  - of refugees and internally displaced persons, 171–72, 177
  - religious and spiritual beliefs, 172
  - risk factors for, 37, 168–71, 173*f*, 178
  - schizophrenia and, 48
  - of sexual minorities, 172
  - stigma of, 176
  - strong personal relationships and, 172
  - substance use disorders and, 51, 55*t*, 110
  - suicide attempt rates, 164–68
    - suicide mortality rates, 164, 165*t*
    - surveillance in LMICs, 168
    - survivors of suicide loss, 172
    - urban vs. rural locations, 170
    - WHO prevention guidelines, 57, 163, 173
    - YLLs and, 53, 55
  - supervised injecting facilities, 57, 115
  - support groups, 192–93, 194. *See also* self-help programs
    - for alcohol use disorders, 136–37
    - for illicit drug dependence, 114, 115*t*
  - suspension of driver's license, 135
  - sustainable development goal (SDG), 2*b*
  - sustained headache relief (SHR), 100
  - Sweden
    - cost of Alzheimer's disease treatment in, 98
    - dementia-related deaths in, 53
    - epilepsy-related deaths in, 52
  - Szekely, A., 176
- T**
- Tanzania
    - epilepsy-related deaths in, 52
    - epilepsy treatment in, 89
  - task-sharing approach, 209–12, 210*b*
  - taxation of alcoholic beverages, 131*t*, 132–33, 138, 221, 229
  - Taylor, B. J., 133–34
  - teacher training program to identify and assess mental health problems, 191, 191*b*
  - TEAMcare USA and TEAMcare Canada, 213
  - telemedicine, 78
  - Ten Questions screen, 151, 151*b*
  - testing
    - blood alcohol concentration (BAC) testing of drivers, 134
    - breath testing of drivers, 134
  - Thailand
    - alcoholic beverages, regulation of, 128
    - antidepressants and CBT as cost-effective interventions for depression in, 225
  - therapeutic community (TC) model, 117
  - Thinking Healthy Programme (Pakistan), 212
  - 3 Dimensions of Care for Diabetes (UK), 213
  - Total Quality Management, 214
  - TPO (Healthnet Transcultural Psychosocial Organization), 17*b*
  - traditional healers, 202
  - traffic accidents. *See* driving impaired and traffic accidents
  - transcranial magnetic stimulation, 74
  - traumatic brain injury, measures to protect against, 186

treatment gap, 214  
in epilepsy, 58, 92*f*  
treatment of MNS disorders, 4*b*, 8–12, 9–11*t*. *See also*  
interventions for MNS disorders  
cost-effectiveness of. *See* cost-effectiveness and  
affordability of interventions  
Ttofi, M. M., 150  
tuberculosis, 50, 129, 212, 213–14  
Turkey  
early childhood enrichment project in, 192  
suicide in, 170, 171

## U

Uganda  
epilepsy treatment in, 89  
specialists training primary health care  
staff in, 210  
United Kingdom  
Alzheimer's disease, pharmacological interventions  
for, 98  
bipolar disorder research in, 48  
cognitive rehabilitation for dementia in, 97  
community-based awareness in, 73  
community-based vs. hospital-based programs  
in, 73  
coping strategy program for mental health of  
dementia caregivers in, 225  
crisis intervention teams in, 77  
epilepsy-related deaths in, 52  
parenting programs in, 223  
3 Dimensions of Care for Diabetes, 213  
United Nations  
Children's Fund Multiple Indicator Cluster  
Survey, 151  
Convention on the Rights of Persons with  
Disabilities, 215  
United States  
court-mandated drug treatment in, 113  
depression in, 69  
Drug Abuse Resistance Education (DARE)  
program, 114  
fetal alcohol syndrome (FAS) warning labels in, 135  
Good Behavior Game for classroom behavior  
management with young children, 114  
stroke awareness program for children in, 189  
TEAMcare USA, 213  
universal health coverage, 5*b*, 18*b*, 19, 237–51. *See also*  
extended cost-effectiveness analysis (ECEA)  
health system goals, 237  
MNS coverage, 237–38  
pay out-of-pocket (OOP) for treatment, 237–38  
University of Washington's Institute for Health Metrics  
and Evaluation, 38

unrecorded market of alcohol production and sales,  
133, 138–39  
urinary tract infections, 53

## V

vicious cycle of social determinants, 3*b*  
violence  
alcohol-attributable, 50, 129  
domestic violence legislation, 186  
Vreeman, R. C., 150

## W

warning labels on alcoholic beverages, 135, 139  
web-based psychological therapy, 15, 78  
Whiteford, H. A., 31  
WHO. *See* World Health Organization  
whole-of-government approach, 205  
whole-of-school approach, 150  
women. *See also* gender differences; pregnancy  
gender equity and economic empowerment  
interventions, 193  
postnatal depression. *See* postpartum depression  
suicide rates of, 171  
workplace interventions, 194  
drug testing, 113–14, 115*t*  
epilepsy, anti-stigma interventions for, 89  
identification and case detection, 188  
mood and anxiety disorders intervention, 73  
promotion and primary prevention, 188  
*World Development Report* (1993), 2*b*  
World Health Organization (WHO)  
Assessment Instrument for Mental Health Systems  
(WHO-AIMS) survey, 73  
*Atlas on Substance Use*, 137  
*Building Back Better*, 204  
*Child and Adolescent Mental Health Policies and  
Plans*, 148  
CHOosing Interventions that are Cost-Effective  
(CHOICE) project, 220, 226, 228, 228*b*, 232  
Comprehensive Mental Health Action Plan, 22, 24  
cost-effectiveness analysis, 18  
detection of mental disorders, system for, 77  
Global Health Estimates, 5, 163, 166*f*  
High-Level Meeting on Non-communicable  
Diseases (2011), 229  
Integrated Management of Adult and Adolescent  
Illness (IMAI), 213  
*List of Essential Medicines*, 57  
Mental Health Gap Action Programme (mhGAP), 1,  
5, 8, 17*b*, 22, 74, 77, 204, 245  
alcohol consumption and, 135, 136  
depression and, 208  
Mental Health Global Action Program, 177

- Ministerial Conference on Global Action Against Dementia (2015), 99
  - noncommunicable disease interventions package, 213
  - Preventing Suicide: A Global Imperative*, 177
  - proposed regional framework in Eastern Mediterranean Region, 23–24*b*
  - Public Health Action for the Prevention of Suicide*, 177
  - on quality improvement (QI) mechanisms, 214
  - QualityRights Project, 186
  - QualityRights Toolkit, 215
  - recommended method for integrating hospital-based and community-based mental health services, 16*b*
  - Service Organization Pyramid for an Optimal Mix of Services for Mental Health*, 202, 202*f*
  - on suicide and suicide prevention, 57, 163, 173, 177, 178
  - World Mental Health Action Plan (2013-2020), 177
  - World Mental Health (WMH) surveys, 69–70, 71, 102, 166
  - YLDs assigned to MNS disorders, 30
  - World Psychiatric Association, 187
- Y**
- years lived with disability (YLDs), 5, 6*f*, 30–31, 35, 35*f*, 37
    - adult mental disorders, 67–68, 68*f*
    - epilepsy, 90
    - from natural history models, 43
    - neurological disorders, 87
    - population attributable fractions (PAFs) and, 44
    - schizophrenia, 68, 68*f*
  - years of life lost (YLLs), 5, 6, 6*f*, 30–31, 35, 35*f*, 37, 41
    - alcohol use disorders, 43–45, 45*f*, 53, 55, 55*t*
    - amphetamine dependence, 43
    - attributions needed for more accurate representation of MNS disorders, 55
    - cause of death and, 42–43, 46, 53–55
    - cocaine dependence, 43
    - dementia, 43, 45*f*
    - depression, 49
    - differences in patterns of MNS prevalence and, 44–45, 45*f*
    - gender differences, 45, 46*f*
    - illicit drug dependence, 45*f*, 53, 110
      - gender differences and, 45, 46*f*
    - natural history models and, 45–46
    - neurological disorders
      - gender differences and, 45, 46*f*
      - regional differences and, 55
    - opioid dependence, 37, 43
    - population attributable fractions (PAFs) and, 44
    - regional differences and, 53–54, 55*f*
    - schizophrenia, 43, 45*f*, 48
    - suicide and, 53, 55
- Z**
- Zambia
    - epilepsy treatment in, 90
    - headache disorders and treatment in, 100, 102, 228*b*
    - trauma-focused CBT for children in, 154